RDY - Dividend announcements

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q1 FY26 Revenues   ₹ 85,452 Mn [Up: 11% YoY; Flat QoQ] Gross Margin   56.9% [Q1FY25: 60.4%; Q4FY25: 55.6%] SG&A Expenses   ₹ 25,647 Mn [Up: 13% YoY; 7% QoQ] R&D Expenses   ₹ 6,244 Mn [7.3% of Revenues] EBITDA   ₹ 22,784 Mn [26.7% of Revenues] Profit before

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY25 FY25   Revenues ₹ 85,060 Mn ₹ 325,535 Mn [Up: 20% YoY^; 2% QoQ] [Up: 17% YoY^]     Gross Margin 55.6% 58.5% [Q4FY24: 58.6%; Q3FY25: 58.7%] [FY24: 58.6%]     SG&A Expenses ₹ 24,055 Mn ₹ 93,870 Mn [Up: 17% YoY; Flat QoQ] [Up: 22% YoY]     R&D Expens

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and nine months ended December 31, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q3FY25 9MFY25   Revenues ₹ 83,586 Mn ₹ 240,475 Mn [Up: 16% YoY^; 4% QoQ] [Up: 15% YoY^]   Gross Margin 58.7% 59.5% [Q3FY24: 58.5%; Q2FY25: 59.6%] [9MFY24: 58.6%]   SG&A Expenses ₹ 24,117 Mn ₹ 69,815 Mn [Up: 19% YoY; 5% QoQ] [Up: 23% YoY]   R&D Expenses ₹ 6,658 Mn ₹ 20,122 Mn [8.0% o

Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY24 FY24   Revenues ₹ 70,830 Mn [Up: 12% YoY; Down: 2% QoQ]^ ₹ 279,164 Mn [Up: 14% YoY]^   Gross Margin 58.6% [Q4FY23: 57.2%; Q3FY24: 58.5%] 58.6% [FY23: 56.7%]   SG&A Expenses ₹ 20,476 Mn [Up: 14% YoY; 1% QoQ] ₹ 77,201 Mn [Up: 13%

Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the quarter ended Sep 30, 2023. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Revenues Rs. 68,802 Mn [Up: 9% YoY; Up: 2% QoQ]   Gross Margin 58.7% [Q2 FY23: 59.1%; Q1 FY24: 58.7%]   SG&A Expenses Rs. 18,795 Mn [Up: 13% YoY; 6% QoQ]   R&D Expenses Rs. 5,447 Mn[7.9% of Revenues]   EBITDA Rs. 21,813 Mn [31.7% of Revenues]   Profit before Tax Rs. 19,134 Mn [Up: 19% YoY; Up: 4% QoQ]  

Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the quarter ended June 30, 2023. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Revenues Rs. 67,384 Mn   [Up: 29%* YoY; Up: 7%* QoQ]     Gross Margin 58.7%   [Q1 FY23: 49.9%; Q4 FY23: 57.2%]     SG&A Expenses Rs. 17,702 Mn   [Up: 14% YoY; Down: 2% QoQ]   R&D Expenses Rs. 4,984 Mn [7.4% of Revenue

Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2023. The information mentioned in this release is on the basis of consolidated financial statements under International Financial Reporting Standards (IFRS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230510005650/en/Q4 FY23 Sales Mix (Graphic: Business Wire) Q4 Performance Summary FY23 Performance Summary   Rs. 6,297 Cr Rs. 24,588 Cr Revenue Revenue [Up: 16% YoY; Down 7% QoQ] [Up: 15% YoY]   57.2% 56.7%